Recent Updates in Diabetes Management
The most transformative updates in diabetes management center on automated insulin delivery systems for Type 1 DM and comorbidity-driven medication selection for Type 2 DM, moving away from glucose-centric approaches toward preventing cardiovascular and renal complications.
Type 1 Diabetes Management Updates
Technology-Driven Revolution
Automated Insulin Delivery (AID) systems are now the recommended standard for most people with T1DM 1. These systems integrate an insulin pump, continuous glucose monitoring (CGM), and computer algorithms to automatically adjust insulin delivery. The evidence shows they increase time-in-range while reducing hypoglycemia compared to traditional methods 1.
The hierarchy of insulin delivery options for T1DM is:
- First-line: AID systems (pump + integrated CGM + algorithm) - Grade A evidence 1
- Second-line: Insulin pump therapy (CSII) with CGM - Grade B evidence 1
- Third-line: Multiple daily injections (MDI) with CGM - Grade A evidence 1
CGM is now the preferred glucose monitoring method for ALL individuals with T1DM, not just those on pumps 1. This represents a major shift from finger-stick monitoring as the default approach.
Insulin Regimen Specifications
Physiologic insulin replacement requires both basal and prandial components 1:
- Basal insulin: 1-2 daily injections of long-acting analogs (U300 glargine or degludec preferred over U100 glargine due to lower hypoglycemia risk) 1
- Prandial insulin: Subcutaneous rapid-acting analogs before each meal, or inhaled insulin as an alternative 1
Insulin analogs are strongly preferred over human insulin for reducing hypoglycemia risk 1, 2.
Critical Education Component
A multi-component diabetes self-management education program is mandatory, ideally delivered by a Certified Diabetes Care and Education Specialist (CDCES) 1. This must cover:
- Carbohydrate counting for prandial insulin dosing
- Exercise and fasting adjustments
- Sick day management and DKA prevention
- Hypoglycemia recognition and treatment
Common pitfall: Failing to provide ongoing education. Education needs must be reassessed regularly as technology and individual circumstances change 1.
Type 2 Diabetes Management Updates
Paradigm Shift: Comorbidity-Centric Approach
The fundamental change in T2DM management is selecting medications based on comorbidities rather than glucose levels alone 3, 4. This approach prioritizes preventing cardiovascular death, heart failure, and kidney disease progression.
Medication Selection Algorithm
For patients with established cardiovascular disease, heart failure, or chronic kidney disease, specific drug classes are now mandatory regardless of A1C:
Heart Failure (HFrEF or HFpEF)
- SGLT2 inhibitor is required for both glycemic management AND prevention of heart failure hospitalizations, irrespective of A1C 3
Chronic Kidney Disease (eGFR 20-60 mL/min/1.73 m² or albuminuria)
- SGLT2 inhibitor OR GLP-1 RA with demonstrated CKD benefit is required for slowing CKD progression and reducing cardiovascular events, irrespective of A1C 3
- Note: SGLT2 inhibitor glycemic benefits diminish at eGFR <45 mL/min/1.73 m² 3
Advanced CKD (eGFR <30 mL/min/1.73 m²)
- GLP-1 RA is preferred due to lower hypoglycemia risk and cardiovascular benefit 3
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
- GLP-1 RA or dual GIP/GLP-1 RA (tirzepatide) for patients with overweight/obesity 3
- For biopsy-proven MASH or high-risk liver fibrosis: pioglitazone, GLP-1 RA, or dual GIP/GLP-1 RA 3
Newer Therapeutic Options
Dual GIP/GLP-1 receptor agonists (tirzepatide) represent a significant advancement, offering superior glycemic control and weight loss compared to single-target agents 5, 3. This multi-targeted approach addresses multiple pathophysiologic defects simultaneously 6.
Oral GLP-1 agonists are now available, improving adherence for patients who prefer oral medications 5.
Insulin Therapy Updates for T2DM
When insulin is needed 7:
- Initiate within 3 months if lifestyle and oral agents fail to achieve targets 7
- Start with basal insulin (long-acting analogs preferred) 7
- For newly diagnosed patients with HbA1c >9.0% or FPG ≥11.1 mmol/L with symptoms: consider short-term intensive insulin therapy (2 weeks to 3 months) 7
GLP-1 RAs can reduce or eliminate bolus insulin requirements in some T2DM patients, addressing both glucose control and weight 1.
Metabolic Surgery Considerations
For T2DM patients with obesity 7:
- Strongly recommended: BMI ≥32.5 kg/m²
- Consider with caution: BMI 27.5-32.5 kg/m² with cardiovascular risk factors
- May consider: BMI 25.0-27.5 kg/m² with central obesity plus ≥2 metabolic syndrome components
Hypoglycemia Management Updates
New glucagon formulations have simplified severe hypoglycemia treatment 1:
- Intranasal glucagon
- Prefilled liquid stable formulations
- Prefilled aqueous glucagon analogs
These eliminate the need for reconstitution, making emergency treatment more practical for caregivers.
Integration of Artificial Intelligence
AI-integrated CGM systems are emerging as tools for predicting hypoglycemia and hyperglycemia, particularly relevant during special circumstances like Ramadan fasting 5. This technology enhances the predictive capabilities beyond current AID systems.
Key Implementation Points
Critical pitfall to avoid: Continuing glucose-centric management in T2DM patients with established cardiovascular or kidney disease. The evidence clearly demonstrates that SGLT2 inhibitors and GLP-1 RAs reduce mortality and major adverse events independent of glucose lowering 3, 8.
Combination therapy at diagnosis can be considered in T2DM to shorten time to glycemic goals 3, representing a departure from traditional stepwise approaches.
Technology access disparities remain a major challenge. While AID systems are recommended for T1DM, many patients globally lack access to basic insulin and glucose monitoring 9. Clinical decisions must account for resource availability.